Delivery Order HHSN261201600019I-HHSN26100002

This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger "Toxicology of Drugs Developed for Cancer Patients" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...

This federal contract award, valued at $3,632,884.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract is for the efficacy and safety evaluation of a lead gene therapy candidate in propionic acidemia (PA) disease mouse models, as well as the development of bioanalytical assay methods. The period of performance is from September...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $114,365 firm fixed price purchase order to Labcorp Early Development Laboratories Inc. to complete the pharmacokinetics portion of the Phase 1 RR-HNK study. Labcorp Early Development Laboratories, a subsidiary of Laboratory Corporation of America Holdings, will perform the work over a two-year period from July 2023 through June 2025 at its facility in Madison,...

This is a federal contract award from the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Battelle Memorial Institute. The $2,611,477.00 cost-plus-fixed-fee contract is for non-GLP dose-range finding and GLP toxicity studies in minipigs, as well as in vitro drug-drug interaction studies for a small peptide. The contract was awarded under the Manufacturing and Nonclinical Studies Support for the...

This is a definitive, firm fixed-price contract awarded by the National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, to Hera Testing Laboratories Inc., a for-profit organization. The contract, valued at $293,728.00, is set aside for small businesses. The purpose of the contract is to contribute to studies of cancer health disparities by generating several patient-derived xenograft (PDX) models for non-small cell lung cancer (NSCLC) in an...

This contract award to Gempharmatech LLC, a foreign-owned biotechnology company in San Diego, California, is for a $58,936 fixed-price purchase order to evaluate the safety of the compound YC1 in mice with humanized SULT1A1 proteins versus standard mouse SULT1A1 proteins. The contract was awarded by the National Center for Advancing Translational Sciences (NCATS), which operates under the National Institutes of Health within the Department of Health and Human Services. The objective is to...

This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI) to Labcorp Early Development Laboratories Inc., a subsidiary of Laboratory Corporation of America Holdings, to provide laboratory testing and quality assurance services for the LMB-100 drug product. The objective is to conduct the required testing and assays to support the Investigational New Drug (IND) application for LMB-100, an anti-mesothelin immunotoxin being developed by NCI's Laboratory of Molecular...

This firm fixed-price purchase order for $86,631 was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Labcorp Early Development Laboratories Inc. to perform 60-month stability testing of two lots of LMB-100 drug product. LMB-100 is an anti-mesothelin immunotoxin under clinical trials for certain cancers. The prime contractor Labcorp will conduct a battery of assays to ensure the identity, potency, and safety of the drug product...

This is a task order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $1,694.39 task order is for a study on the pharmacodynamics of a MAS-related gene X2 (MRGX2) antagonist in a humanized MRGX2 knock-in mouse model. The work falls under an Indefinite Delivery Indefinite Quantity (IDIQ) contract awarded by NCATS for medicinal chemistry and...

<p>This is a $224,363 firm-fixed-price federal contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. government, to LP Therapeutics, Inc., a small business. The contract is for the development of nanoparticles to eradicate leukemia stem cells. The award has a completion date of July 31, 2015. This contract appears to be a standalone award, not associated with a larger contract vehicle.</p>